Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial - The Lancet Gastroenterology & Hepatology
Remicade® (infliximab): 20 years of contributions to science and m | BTT
Remicade (infliximab): Uses, Side Effects, Dosage & Reviews
Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence
AVSOLA®(infliximab-axxq)'s Totality of Evidence
Samsung Bioepis and Merck Launch Renflexis® in the U.S. | Biosimilars Law Bulletin
Biosimilars of infliximab
Pivotal Clinical Trials
REMICADE 100mg - Buy online in OGOmed
U.S. Biosimilar Launches Accelerate with Five Launches in Q4 2019 and early 2020 | Biosimilars Law Bulletin
J&J braces for biosim attack after losing last-ditch Remicade patent fight | Fierce Pharma
REMICADE® (infliximab) Overview | Janssen CarePath for Healthcare Professionals
The US Biosimilar Market Where Is It Today And Where Is It Going
Subcutaneous Infliximab In The US Defining CT-P13 SC's Competitive Edge
Biosimilar strategy for infliximab by MedDrive™ includes the reference drug - Prime Therapeutics LLC
FDA Approves First Subcutaneous Infliximab for IBD
AVSOLA®(infliximab-axxq)'s Totality of Evidence
Celltrion Scores FDA Approval of SC Infliximab: Will Use of the IV Formulation Be Affected? | BR&R
Avsola (infliximab-axxq) FDA Approval History - Drugs.com
Remicade (infliximab): Side effects, dosage, cost, and more
Report on EU's Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar? - Page 2 of 5 - The Rheumatologist
REMICADE® (infliximab) Overview | Janssen CarePath for Healthcare Professionals
U.S. Biosimilar Launches Accelerate with Five Launches in Q4 2019 and early 2020 | Biosimilars Law Bulletin
